VistaGen Therapeutics Inc./$VTGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
Ticker
$VTGN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
48
ISIN
US92840H4002
Website
VTGN Metrics
BasicAdvanced
$68M
-
-$1.55
0.62
-
Price and volume
Market cap
$68M
Beta
0.62
52-week high
$2.96
52-week low
$1.90
Average daily volume
129K
Financial strength
Current ratio
9.348
Quick ratio
9.205
Long term debt to equity
1.368
Total debt to equity
2.112
Management effectiveness
Return on assets (TTM)
-29.57%
Return on equity (TTM)
-46.28%
Valuation
Price to revenue (TTM)
103.522
Price to book
0.82
Price to tangible book (TTM)
0.82
Price to free cash flow (TTM)
-1.846
Growth
Revenue change (TTM)
-33.07%
Earnings per share change (TTM)
-34.81%
3-year revenue growth (CAGR)
-22.71%
3-year earnings per share growth (CAGR)
-46.53%
VTGN News
AllArticlesVideos
Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
Business Wire·6 days ago
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for VistaGen Therapeutics Inc. stock?
VistaGen Therapeutics Inc. (VTGN) has a market cap of $68M as of June 08, 2025.
What is the P/E ratio for VistaGen Therapeutics Inc. stock?
The price to earnings (P/E) ratio for VistaGen Therapeutics Inc. (VTGN) stock is 0 as of June 08, 2025.
Does VistaGen Therapeutics Inc. stock pay dividends?
No, VistaGen Therapeutics Inc. (VTGN) stock does not pay dividends to its shareholders as of June 08, 2025.
When is the next VistaGen Therapeutics Inc. dividend payment date?
VistaGen Therapeutics Inc. (VTGN) stock does not pay dividends to its shareholders.
What is the beta indicator for VistaGen Therapeutics Inc.?
VistaGen Therapeutics Inc. (VTGN) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.